Rak jajnika: badanie obserwacyjne

Kryteria włączenia kto może wziąć udział (16)

1. Patients must be female, ≥18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent.
2. Patients with a histologically confirmed diagnosis of nonmucinous high - grade epithelial ovarian cancer (serous, endometrial) that is stage III or IV according to the FIGO criteria.
3. All patients with Stage IV disease are eligible. This includes those with inoperable disease, those who undergo PDS (R0 or macroscopic disease), or those for whom NACT is planned.
4. Patients with Stage III are eligible if they meet the following criteria:
5. All FIGO III patients in spite of residual disease and cytoreductive surgery.
6. All patients with inoperable Stage III disease.
7. All Stage III patients after NACT chemotherapy.
8. FFPE tumor tissue sample must be available for molecular analysis.
9. Patients of childbearing potential must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin) within 72 hours prior to receiving the first dose of study treatment.
10. Patients must be postmenopausal, free from menses for >1 year, surgically sterilized, or willing to use highly effective contraception to prevent pregnancy (see 0) or must agree to abstain from activities that could result in pregnancy throughout the study, starting with enrollment through 180 days after the last dose of study treatment.
11. Serum creatinine ≤1.5 × upper limit of normal (ULN) or calculated creatinine clearance ≥60 mL/min using the Cockcroft-Gault equation
12. Total bilirubin ≤1.5 × ULN or direct bilirubin ≤1.5 × ULN
13. AST and ALT ≤2.5 × ULN unless liver metastases are present, in which case they must be ≤5 × ULN
14. Patients must have an ECOG score of 0 or 1.
15. Patients must have normal BP or adequately treated and controlled hypertension.
16. Patients must be able to take oral medication.